Compare COLL & LGIH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLL | LGIH |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2015 | 2013 |
| Metric | COLL | LGIH |
|---|---|---|
| Price | $37.27 | $44.52 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | $50.83 | ★ $75.90 |
| AVG Volume (30 Days) | ★ 364.8K | 339.8K |
| Earning Date | 05-28-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.73 | ★ 3.12 |
| Revenue | $780,567,000.00 | ★ $1,705,504,000.00 |
| Revenue This Year | $6.07 | $6.01 |
| Revenue Next Year | N/A | $14.33 |
| P/E Ratio | $21.50 | ★ $15.06 |
| Revenue Growth | ★ 23.62 | N/A |
| 52 Week Low | $23.23 | $39.70 |
| 52 Week High | $50.79 | $77.38 |
| Indicator | COLL | LGIH |
|---|---|---|
| Relative Strength Index (RSI) | 21.42 | 30.01 |
| Support Level | $34.30 | $41.82 |
| Resistance Level | $39.85 | $55.90 |
| Average True Range (ATR) | 1.61 | 2.57 |
| MACD | -0.83 | -1.29 |
| Stochastic Oscillator | 9.89 | 1.04 |
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company have seven operating segments ( West, Northwest, Central, Midwest, Florida, Southeast and Mid-Atlantic) that it aggregates into five qualifying reportable segment. Majority of the revenue is generated from Central division segment.